These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12815479)

  • 1. Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab.
    Galimberti S; Guerrini F; Morabito F; Palumbo GA; Di Raimondo F; Papineschi F; Caracciolo F; Fazzi R; Cervetti G; Cuzzocrea A; Petrini M
    Bone Marrow Transplant; 2003 Jul; 32(1):57-63. PubMed ID: 12815479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma.
    Berinstein NL; Buckstein R; Imrie K; Spaner D; Mangel J; Tompkins K; Pennell N; Reis M; Pavlin P; Lima A; Couvadia A; Robinson J; Richardson P
    Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S14-7. PubMed ID: 11840156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy.
    Martin S; Fischer C; Free M; Kurreck B; Stockinger H; Fenk R; Arnold C; Kliszewski S; Meckenstock G; Haas R; Kronenwett R
    Eur J Haematol; 2005 Apr; 74(4):282-92. PubMed ID: 15777339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
    Arcaini L; Orlandi E; Alessandrino EP; Iacona I; Brusamolino E; Bonfichi M; Bernasconi P; Calatroni S; Tenore A; Montanari F; Troletti D; Pascutto C; Regazzi M; Lazzarino M
    Bone Marrow Transplant; 2004 Jul; 34(2):175-9. PubMed ID: 15170171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in autologous stem cell transplantation for follicular lymphoma.
    Schmitz N
    Anticancer Drugs; 2001 Jun; 12 Suppl 2():S21-4. PubMed ID: 11508933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
    Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B
    J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma.
    Endo T; Sato N; Mogi Y; Koizumi K; Nishio M; Fujimoto K; Sakai T; Kumano K; Obara M; Ikeda H; Koike T
    Bone Marrow Transplant; 2004 Apr; 33(7):703-7. PubMed ID: 14743197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma.
    Friedberg JW; Kim H; Li S; Neuberg D; Boyd K; Daley H; Fisher DC; Gribben JG; Spitzer T; Freedman AS
    Bone Marrow Transplant; 2003 Oct; 32(7):681-6. PubMed ID: 13130315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma.
    Arcaini L; Montanari F; Alessandrino EP; Tucci A; Brusamolino E; Gargantini L; Cairoli R; Bernasconi P; Passamonti F; Bonfichi M; Zoli V; Bottelli C; Calatroni S; Troletti D; Merli M; Pascutto C; Majolino I; Rossi G; Morra E; Lazzarino M
    Ann Oncol; 2008 Jul; 19(7):1331-1335. PubMed ID: 18344536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficiency of in vivo purging with autologous stem cell transplantation and monoclonal antibody in B-cell lymphomas.
    Tóthová E; Kafková A; Guman T; Stecová N; Fricová M
    Neoplasma; 2003; 50(1):22-5. PubMed ID: 12687274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma.
    Kang TY; Rybicki LA; Bolwell BJ; Thakkar SG; Brown S; Dean R; Sekeres MA; Advani A; Sobecks R; Kalaycio M; Pohlman B; Sweetenham JW
    Bone Marrow Transplant; 2007 Nov; 40(10):973-8. PubMed ID: 17873917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
    Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma.
    Hicks LK; Woods A; Buckstein R; Mangel J; Pennell N; Zhang L; Imrie K; Spaner D; Cheung MC; Boudreau A; Reis M; Crump M; Berinstein NL
    Bone Marrow Transplant; 2009 May; 43(9):701-8. PubMed ID: 19029963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells].
    Schüler F; Hirt C; Dölken L; Krüger W; Dölken G
    Dtsch Med Wochenschr; 2005 Sep; 130(38):2130-4. PubMed ID: 16172952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
    Schmitt C; Grundt A; Buchholtz C; Scheuer L; Benner A; Hensel M; Ho AD; Leo E
    Leuk Res; 2006 Dec; 30(12):1563-8. PubMed ID: 16530831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.
    van Heeckeren WJ; Vollweiler J; Fu P; Cooper BW; Meyerson H; Lazarus HM; Simic A; Laughlin MJ; Gerson SL; Koç ON
    Br J Haematol; 2006 Jan; 132(1):42-55. PubMed ID: 16371019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PCR study of bcl-2 rearrangement in autologous transplantation of peripheral stem cells in follicular non-Hodgkin's lymphoma].
    Ataulfo González F; Armada B; Villegas A; Llorente L; Pérez J; Díaz Mediavilla J; del Potro E; Martínez R; Alvarez A; Espinós D
    Med Clin (Barc); 1997 May; 108(19):730-3. PubMed ID: 9324596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
    Blystad AK; Delabie J; Kvaløy S; Holte H; Vålerhaugen H; Ikonomou I; Kvalheim G
    Br J Haematol; 2004 Jun; 125(5):605-12. PubMed ID: 15147376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation.
    Cairoli R; Grillo G; Tedeschi A; D'Avanzo G; Marenco P; Morra E
    Haematologica; 2004 Mar; 89(3):361-3. PubMed ID: 15020279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction.
    Pennell N; Woods A; Reis M; Buckstein R; Spaner D; Imrie K; Hewitt K; Boudreau A; Seth A; Berinstein NL
    J Mol Diagn; 2006 Feb; 8(1):40-50. PubMed ID: 16436633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.